Previous 10 | Next 10 |
2023-07-31 08:19:22 ET Checkpoint Therapeutics ( CKPT ) -14% announces $10 Million registered direct offering priced at-the-market. Citius Pharmaceuticals ( CTXR ) -13% . BioNexus Gene Lab Corp. ( BGLC ) -13% . Blue Star Foods Corp. ( BSFC ) -...
Citius Pharmaceuticals, Inc. Receives a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for LYMPHIR™ (Denileukin Diftitox) for the Treatment of Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma PR Newswire No clinical efficacy or s...
2023-06-26 09:11:09 ET Citius Pharmaceuticals ( NASDAQ: CTXR ) said on Monday that it will be join the Russell 3000 and Russell 2000 indexes at the end of the annual reconstitution of Russell US Indexes, effective after U.S. markets open on June 26. ...
Citius Pharmaceuticals to be Added to Russell 3000® and Russell 2000® Indexes PR Newswire CRANFORD, N.J. , June 26, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company...
2023-06-20 09:23:59 ET Shares of Citius Pharmaceuticals ( NASDAQ: CTXR ) gained ~5% pre-market Tuesday after announcing Halo-Lido, a topical treatment comprising lidocaine and halobetasol for hemorrhoid relief, outperformed in a Phase 2b trial. The randomized trial involving...
Citius Pharmaceuticals Announces Positive Results from the Phase 2b Study of Halo-Lido (CITI-002) for the Treatment of Hemorrhoids PR Newswire CITI-002 provides a meaningful reduction in symptom severity when compared to individual components alone Dose for Phase 3 tri...
Citius Pharmaceuticals to Participate in Maxim Group's Virtual Healthcare Conference on June 21, 2023 PR Newswire CRANFORD, N.J. , June 13, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutica...
2023-06-02 18:55:19 ET Summary The article provides an updated analysis of Citius Pharmaceuticals following a previous piece in February 2023. Citius' lead therapy has a midsummer 2023 PDUFA; it has generated excitement among investors, although it is unlikely to generate alpha. ...
2023-05-24 13:57:04 ET The Russell 3000 index will have a new look on June 26, after the market opens, when 286 securities will be added and 179 securities will be deleted as part of the annual reconstitution. Following are some notable healthcare companies which will be added an...
2023-05-12 17:00:00 ET Citius Pharmaceuticals press release ( NASDAQ: CTXR ): Q2 GAAP EPS of -$0.07 misses by $0.02 . Cash and cash equivalents of $29.1 million as of March 31, 2023; $15 million in gross proceeds from equity financing as of May 8, 202. For furthe...
News, Short Squeeze, Breakout and More Instantly...
Citius Pharmaceuticals Inc. Company Name:
CTXR Stock Symbol:
NASDAQ Market:
Citius Pharmaceuticals Inc. Website:
2024-07-18 10:20:00 ET July 18, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the second of a two-part series looking at biotech/biopharma stocks, featuring Citius Pharmaceuticals, Inc. ( Nasdaq:CTXR ), a late-stage biopharmaceutical compa...
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - July 18, 2024) - Investorideas.com , a go-to investing platform releases the second of a two-part series looking at biotech/biopharma stocks, featuring Citius Pharmaceuticals, Inc. (NASDAQ: CTXR), a late-stage biopharmaceutical c...
2024-07-17 10:10:00 ET July 17, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the first of a two-part series looking at biotech/biopharma stocks, featuring Citius Pharmaceuticals, Inc. ( Nasdaq:CTXR ), a late-stage biopharmaceutical compan...